Denali Therapeutics Inc
DNLI
View Detailed Chart
16.510USD
+0.100+0.61%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
2.42BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.61%
5 Days
-2.83%
1 Month
-15.20%
6 Months
+18.01%
Year to Date
0.00%
1 Year
-18.99%
View Detailed Chart
TradingKey Stock Score of Denali Therapeutics Inc
Currency: USD Updated: 2025-12-31Key Insights
Denali Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 77/403 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 32.29.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Denali Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Strong Buy
Current Rating
32.286
Target Price
+63.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Denali Therapeutics Inc Highlights
StrengthsRisks
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -5.67, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 148.33M shares, increasing 0.02% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 56.37K shares of this stock.
Denali Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Denali Therapeutics Inc Info
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Ticker SymbolDNLI
CompanyDenali Therapeutics Inc
CEOWatts (Ryan J)
Websitehttps://www.denalitherapeutics.com
FAQs
What is the current price of Denali Therapeutics Inc (DNLI)?
The current price of Denali Therapeutics Inc (DNLI) is 16.510.
What is the symbol of Denali Therapeutics Inc?
The ticker symbol of Denali Therapeutics Inc is DNLI.
What is the 52-week high of Denali Therapeutics Inc?
The 52-week high of Denali Therapeutics Inc is 24.345.
What is the 52-week low of Denali Therapeutics Inc?
The 52-week low of Denali Therapeutics Inc is 10.570.
What is the market capitalization of Denali Therapeutics Inc?
The market capitalization of Denali Therapeutics Inc is 2.42B.
What is the net income of Denali Therapeutics Inc?
The net income of Denali Therapeutics Inc is -422.77M.
Is Denali Therapeutics Inc (DNLI) currently rated as Buy, Hold, or Sell?
According to analysts, Denali Therapeutics Inc (DNLI) has an overall rating of --, with a price target of 32.286.
What is the Earnings Per Share (EPS TTM) of Denali Therapeutics Inc (DNLI)?
The Earnings Per Share (EPS TTM) of Denali Therapeutics Inc (DNLI) is -2.912.
Related Instruments
-0.46%
+0.03%
-0.55%
-0.63%
-0.61%
-0.74%
-0.42%
-0.65%
-0.36%
-0.36%
-0.57%
-0.08%
-0.48%
-0.86%
-0.53%
+0.45%
-0.27%
0.00%
-0.46%
+0.10%
